New Technologies in Cervical Cancer Screening

Patti E. Gravitt, François Coutlée, Thomas Iftner, John W. Sellors, Wim G V Quint, Cosette M. Wheeler

Research output: Contribution to journalArticle

Abstract

A shift to a molecular approach to cervical cancer screening is the most likely solution to the goals of improved screening in both the developed and developing world. The impetus for new screening technologies in the developed world is predominately driven by the need to increase positive predictive value and reduce over-management of low-grade and often transient abnormalities (i.e., increase specificity). Rapid tests, where results can be given to a patient within the same visit, are anticipated to have the greatest impact in low resource settings in low and middle income countries (and in disadvantaged sub-populations in high-income countries) where substantial loss to follow up cripples the effectiveness of cervical cancer screening programs. Clinical validation will be required before these tests are implemented in routine screening programs.

Original languageEnglish (US)
JournalVaccine
Volume26
Issue numberSUPPL. 10
DOIs
StatePublished - Aug 19 2008

Fingerprint

uterine cervical neoplasms
Early Detection of Cancer
Uterine Cervical Neoplasms
screening
Technology
Vulnerable Populations
income
testing

Keywords

  • Cervical cancer
  • HPV
  • HPV DNA
  • Screening
  • Technology

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Gravitt, P. E., Coutlée, F., Iftner, T., Sellors, J. W., Quint, W. G. V., & Wheeler, C. M. (2008). New Technologies in Cervical Cancer Screening. Vaccine, 26(SUPPL. 10). https://doi.org/10.1016/j.vaccine.2008.05.002

New Technologies in Cervical Cancer Screening. / Gravitt, Patti E.; Coutlée, François; Iftner, Thomas; Sellors, John W.; Quint, Wim G V; Wheeler, Cosette M.

In: Vaccine, Vol. 26, No. SUPPL. 10, 19.08.2008.

Research output: Contribution to journalArticle

Gravitt, PE, Coutlée, F, Iftner, T, Sellors, JW, Quint, WGV & Wheeler, CM 2008, 'New Technologies in Cervical Cancer Screening', Vaccine, vol. 26, no. SUPPL. 10. https://doi.org/10.1016/j.vaccine.2008.05.002
Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WGV, Wheeler CM. New Technologies in Cervical Cancer Screening. Vaccine. 2008 Aug 19;26(SUPPL. 10). https://doi.org/10.1016/j.vaccine.2008.05.002
Gravitt, Patti E. ; Coutlée, François ; Iftner, Thomas ; Sellors, John W. ; Quint, Wim G V ; Wheeler, Cosette M. / New Technologies in Cervical Cancer Screening. In: Vaccine. 2008 ; Vol. 26, No. SUPPL. 10.
@article{2623353f4e91468b8e63932cc69eb577,
title = "New Technologies in Cervical Cancer Screening",
abstract = "A shift to a molecular approach to cervical cancer screening is the most likely solution to the goals of improved screening in both the developed and developing world. The impetus for new screening technologies in the developed world is predominately driven by the need to increase positive predictive value and reduce over-management of low-grade and often transient abnormalities (i.e., increase specificity). Rapid tests, where results can be given to a patient within the same visit, are anticipated to have the greatest impact in low resource settings in low and middle income countries (and in disadvantaged sub-populations in high-income countries) where substantial loss to follow up cripples the effectiveness of cervical cancer screening programs. Clinical validation will be required before these tests are implemented in routine screening programs.",
keywords = "Cervical cancer, HPV, HPV DNA, Screening, Technology",
author = "Gravitt, {Patti E.} and Fran{\cc}ois Coutl{\'e}e and Thomas Iftner and Sellors, {John W.} and Quint, {Wim G V} and Wheeler, {Cosette M.}",
year = "2008",
month = "8",
day = "19",
doi = "10.1016/j.vaccine.2008.05.002",
language = "English (US)",
volume = "26",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "SUPPL. 10",

}

TY - JOUR

T1 - New Technologies in Cervical Cancer Screening

AU - Gravitt, Patti E.

AU - Coutlée, François

AU - Iftner, Thomas

AU - Sellors, John W.

AU - Quint, Wim G V

AU - Wheeler, Cosette M.

PY - 2008/8/19

Y1 - 2008/8/19

N2 - A shift to a molecular approach to cervical cancer screening is the most likely solution to the goals of improved screening in both the developed and developing world. The impetus for new screening technologies in the developed world is predominately driven by the need to increase positive predictive value and reduce over-management of low-grade and often transient abnormalities (i.e., increase specificity). Rapid tests, where results can be given to a patient within the same visit, are anticipated to have the greatest impact in low resource settings in low and middle income countries (and in disadvantaged sub-populations in high-income countries) where substantial loss to follow up cripples the effectiveness of cervical cancer screening programs. Clinical validation will be required before these tests are implemented in routine screening programs.

AB - A shift to a molecular approach to cervical cancer screening is the most likely solution to the goals of improved screening in both the developed and developing world. The impetus for new screening technologies in the developed world is predominately driven by the need to increase positive predictive value and reduce over-management of low-grade and often transient abnormalities (i.e., increase specificity). Rapid tests, where results can be given to a patient within the same visit, are anticipated to have the greatest impact in low resource settings in low and middle income countries (and in disadvantaged sub-populations in high-income countries) where substantial loss to follow up cripples the effectiveness of cervical cancer screening programs. Clinical validation will be required before these tests are implemented in routine screening programs.

KW - Cervical cancer

KW - HPV

KW - HPV DNA

KW - Screening

KW - Technology

UR - http://www.scopus.com/inward/record.url?scp=50849118441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50849118441&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.05.002

DO - 10.1016/j.vaccine.2008.05.002

M3 - Article

C2 - 18847556

AN - SCOPUS:50849118441

VL - 26

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - SUPPL. 10

ER -